PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 112, Issue 11, Pages 3493-3498
Publisher
Proceedings of the National Academy of Sciences
Online
2015-03-03
DOI
10.1073/pnas.1420785112
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
- (2015) A. Song et al. CLINICAL CANCER RESEARCH
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- (2014) Tatsushi Kodama et al. CANCER LETTERS
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
- (2014) Qinhua Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
- (2014) Ted W. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
- (2014) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
- (2014) Thomas Wiesner et al. Nature Communications
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
- (2013) Lynette M. Sholl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches
- (2013) Huiyong Sun et al. Journal of Chemical Information and Modeling
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
- (2013) Mikko Taipale et al. NATURE BIOTECHNOLOGY
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
- (2013) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
- (2013) M. A. Davare et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types
- (2013) Craig P. Giacomini et al. PLoS Genetics
- Abstract 3764: SC-1, a sorafenib derivative, induces apoptosis in epidermal growth factor receptor wild type non-small cell lung cancer through the inhibition of signal transducers and activators of transcription 3
- (2012) Cheng-Yi Wang et al. CANCER RESEARCH
- Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
- (2012) V. M. Rimkunas et al. CLINICAL CANCER RESEARCH
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- (2012) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
- (2012) Sai-Hong Ignatius Ou et al. Expert Review of Anticancer Therapy
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
- (2011) Ting-Lei Gu et al. PLoS One
- Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
- (2011) Ashley H. Birch et al. PLoS One
- A Cre/LoxP conditional luciferase reporter transgenic mouse for bioluminescence monitoring of tumorigenesis
- (2009) Steve Woolfenden et al. GENESIS
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started